- CA$5.08m
- CA$5.12m
- CA$1.18m
- 24
- 18
- 48
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.96 | ||
| Price to Tang. Book | 8.8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -51.99% | ||
| Return on Equity | -41.04% | ||
| Operating Margin | -39.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.99 | 1.19 | 1.48 | 1.13 | 1.18 | n/a | n/a | 7.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +399.31 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.
Directors
- James Timourian CHM
- Alan Savage CFO
- Bernard Grobbelaar DRC
- Karen Farkas IND
- Craig Milne IND
- David Tam IND
- Gerard Tertzakian IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 30th, 2006
- Public Since
- May 28th, 2003
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 39,043,612
- Address
- 2011 94 St NW Suite 101, EDMONTON, T6N 1H1
- Web
- https://innovotech.ca/
- Phone
- +1 7804480585
- Auditors
- D&H Group LLP
Upcoming Events for IOT
Similar to IOT
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
Kane Biotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
FAQ
What is the Innovotech share price?
As of Today at 21:20 UTC, shares in Innovotech are trading at CA$0.13. This share price information is delayed by 15 minutes.
How has the Innovotech share price performed this year?
Shares in Innovotech last closed at CA$0.13 and the price had moved by +30% over the past 365 days. In terms of relative price strength the Innovotech share price has outperformed the Toronto Stock Exchange 300 Composite Index by +14.55% over the past year.
What are the analyst and broker recommendations for Innovotech?
There is no consensus recommendation for this security.
Find out moreWhat is the Innovotech dividend yield?
Innovotech does not currently pay a dividend.
Does Innovotech pay a dividend?
Innovotech does not currently pay a dividend.
When does Innovotech next pay dividends?
Innovotech does not currently pay a dividend.
How do I buy Innovotech shares?
To buy shares in Innovotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Innovotech?
As of the previous close price of CA$0.13, shares in Innovotech had a market capitalisation of CA$5.08m.
Where are Innovotech shares listed?
Here are the trading details for Innovotech:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: IOT
What kind of share is Innovotech?
Based on an overall assessment of its quality, value and momentum Innovotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Innovotech share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Innovotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Innovotech. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +24.22%.
As of the last closing price of CA$0.13, shares in Innovotech were trading -7.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Innovotech PE Ratio?
The Innovotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Innovotech?
Innovotech's management team is headed by:
- James Timourian - CHM
- Alan Savage - CFO
- Bernard Grobbelaar - DRC
- Karen Farkas - IND
- Craig Milne - IND
- David Tam - IND
- Gerard Tertzakian - IND